BioLineRx Ltd BLRX
Annual
Quarterly
FY2025 · ended Dec 31, 2025 · Revenue $1.18M, -95.9% YoY · Filed Mar 23, 2026
BioLineRx Ltd (BLRX) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.2 million and a net loss of $2.0 million. Free cash flow was -$8.1 million. As of Dec 31, 2025 it held $3.2 million in cash and investments and $1.2 million in total debt.
Revenue
$1.18M
-95.9% vs prior year
Net income
$-2.03M
+78.0% vs prior year
Operating cash flow
$-8.07M
+81.6% vs prior year
Free cash flow
$-8.10M
+81.6% vs prior year
EPS
$0.00
+100.0% vs prior year
Dividend per share
None
Shares outstanding
2.61B
+16.9% vs prior year
Net cash
$2.04M
FY 2025
Operating margin
-871.8%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BLRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Israel
- Headquarters
- Modi-In
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1498403
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.2M | $28.9M | $4.8M | — | — |
| Operating income | -$10.3M | -$20.4M | -$49.7M | -$29.2M | -$24.8M |
| Net income | -$2.0M | -$9.2M | -$60.6M | -$25.0M | -$27.1M |
| Diluted EPS | $0.00 | -$0.01 | -$0.06 | -$0.03 | — |
| Operating cash flow | -$8.1M | -$43.9M | -$22.6M | -$26.2M | -$23.6M |
| Free cash flow | -$8.1M | -$43.9M | -$22.7M | -$26.4M | -$23.7M |
| Total assets | $40.9M | $38.9M | $63.9M | $76.4M | $81.4M |
| Total liabilities | $17.6M | $25.4M | $50.7M | $25.5M | $13.3M |
| Stockholders' equity | $23.3M | $13.5M | $13.2M | $50.8M | $68.1M |
| Cash and investments | $3.2M | $10.4M | $4.3M | $10.6M | $13.0M |
| Total debt | $1.2M | $1.6M | $1.8M | $2.2M | $1.9M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Oct 23, 2026 | Oct 23, 2026 |
| 6-K | Current report (foreign issuer) | Sep 24, 2026 | Sep 24, 2026 |
| 6-K | Current report (foreign issuer) | Sep 10, 2026 | Sep 10, 2026 |
| 6-K | Current report (foreign issuer) | Aug 31, 2026 | Aug 31, 2026 |
| 6-K | Current report (foreign issuer) | Aug 31, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | Aug 28, 2026 | Aug 28, 2025 |
All 617 BioLineRx Ltd SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.